Foghorn Therapeutics FHTX Stock
Foghorn Therapeutics Price Chart
Foghorn Therapeutics FHTX Financial and Trading Overview
Foghorn Therapeutics stock price | 3.44 USD |
Previous Close | 8.19 USD |
Open | 8.21 USD |
Bid | 0 USD x 1000 |
Ask | 0 USD x 900 |
Day's Range | 8.16 - 8.72 USD |
52 Week Range | 4.51 - 18.12 USD |
Volume | 87.38K USD |
Avg. Volume | 90.33K USD |
Market Cap | 355.93M USD |
Beta (5Y Monthly) | 2.162042 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.58 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 16.33 USD |
FHTX Valuation Measures
Enterprise Value | 76.41M USD |
Trailing P/E | N/A |
Forward P/E | -3.2357414 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 17.263863 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 3.706 |
Enterprise Value/EBITDA | -0.641 |
Trading Information
Foghorn Therapeutics Stock Price History
Beta (5Y Monthly) | 2.162042 |
52-Week Change | -28.84% |
S&P500 52-Week Change | 20.43% |
52 Week High | 18.12 USD |
52 Week Low | 4.51 USD |
50-Day Moving Average | 6.75 USD |
200-Day Moving Average | 7.21 USD |
FHTX Share Statistics
Avg. Volume (3 month) | 90.33K USD |
Avg. Daily Volume (10-Days) | 85.08K USD |
Shares Outstanding | 41.82M |
Float | 20.21M |
Short Ratio | 21.33 |
% Held by Insiders | 26.10% |
% Held by Institutions | 63.43% |
Shares Short | 2.12M |
Short % of Float | 7.50% |
Short % of Shares Outstanding | 5.05% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -594.89% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -17.80% |
Return on Equity (ttm) | -470.37% |
Income Statement
Revenue (ttm) | 20.62M USD |
Revenue Per Share (ttm) | 0.49 USD |
Quarterly Revenue Growth (yoy) | 35.39% |
Gross Profit (ttm) | -86390000 USD |
EBITDA | -119281000 USD |
Net Income Avi to Common (ttm) | -112456000 USD |
Diluted EPS (ttm) | -2.59 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 315.97M USD |
Total Cash Per Share (mrq) | 7.56 USD |
Total Debt (mrq) | 49.84M USD |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 5.748 |
Book Value Per Share (mrq) | -0.588 |
Cash Flow Statement
Operating Cash Flow (ttm) | -109102000 USD |
Levered Free Cash Flow (ttm) | -51555248 USD |
Profile of Foghorn Therapeutics
Country | United States |
State | MA |
City | Cambridge |
Address | 500 Technology Square |
ZIP | 02139 |
Phone | 617 586 3100 |
Website | https://foghorntx.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 161 |
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Q&A For Foghorn Therapeutics Stock
What is a current FHTX stock price?
Foghorn Therapeutics FHTX stock price today per share is 3.44 USD.
How to purchase Foghorn Therapeutics stock?
You can buy FHTX shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Foghorn Therapeutics?
The stock symbol or ticker of Foghorn Therapeutics is FHTX.
Which industry does the Foghorn Therapeutics company belong to?
The Foghorn Therapeutics industry is Biotechnology.
How many shares does Foghorn Therapeutics have in circulation?
The max supply of Foghorn Therapeutics shares is 55.61M.
What is Foghorn Therapeutics Price to Earnings Ratio (PE Ratio)?
Foghorn Therapeutics PE Ratio is now.
What was Foghorn Therapeutics earnings per share over the trailing 12 months (TTM)?
Foghorn Therapeutics EPS is -1.58 USD over the trailing 12 months.
Which sector does the Foghorn Therapeutics company belong to?
The Foghorn Therapeutics sector is Healthcare.
Foghorn Therapeutics FHTX included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
NASDAQ Global Market Composite NQGM | 1647.83 USD — |
-5.17
|
— — | 1610.28 USD — | 1681.06 USD — | — - | — — |
NASDAQ Biotechnology NBI | 3904.12 USD — |
-5.49
|
— — | 3901.51 USD — | 4064.61 USD — | — - | — — |
NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
- {{ link.label }} {{link}}